Real-world evidence of nivolumab for non-small-cell lung cancer in a developing country

无容量 医学 中止 四分位间距 内科学 肺癌 肿瘤科 置信区间 回顾性队列研究 癌症 外科 免疫疗法
作者
Mauricio Luján,Mauricio Lema,Beatriz Preciado,Camila Lema,Jorge Egurrola,Andrés F. Cardona,Diego González,William Mantilla,Luís Pino,Gustavo Bueno Rojas,Diego Hernán Arias Gómez,Isabel Munévar,Raimundo Manneh,Ray Manneh Kopp,José Lobatón,Esteban Calle,Mariana Borras Osorio,Iván Triana,P.A. Londoño,Sandra Aruachán
出处
期刊:Journal of Investigative Medicine [SAGE Publishing]
卷期号:71 (5): 502-510 被引量:1
标识
DOI:10.1177/10815589221147897
摘要

Nivolumab is a human programmed death receptor-1 blocking antibody, used as treatment option in patients with advanced non-small-cell lung cancer (NSCLC). We assessed the nivolumab efficacy in terms of survival and response to treatment as second-line (2L) or third-line (3L) therapy in patients with advanced NSCLC. This is a multicentric observational study. Data of patients with advanced NSCLC who received nivolumab as 2L or 3L treatment were analyzed retrospectively. Information regarding patient demographics and clinical backgrounds, treatment patterns from diagnosis to post-nivolumab treatment, effectiveness, and safety of nivolumab treatment were collected. The outcomes evaluated were overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) to treatment. OS and PFS were estimated with the Kaplan-Meier method and the differences were evaluated through the log-rank test. Data of 178 patients were included. The median follow-up was 26.8 months (interquartile range (IQR): 20.3-40.4). Nivolumab was commonly used as a 2L treatment (77.5%). The outcomes in this setting (2L) were as follows: ORR was 21.0%, and the median PFS and OS were 5.5 months (95% confidence interval (CI): 4.5-6.5) and 12.4 months (95% CI: 10.8-14.0), respectively. In 3L, the ORR with nivolumab was 15.0%, the median PFS and OS were 4.1 months (95% CI: 3.1-5.1) and 10.1 months (95% CI: 9.4-10.6), respectively. Three patients (1.7%) required discontinuation due to toxicity. Nivolumab effectiveness and safety in this scenario was consistent with that reported by previous trials and other real-world data.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
王chun发布了新的文献求助10
1秒前
华仔的应助被123采纳,获得10
1秒前
开朗的雁完成签到,获得积分10
2秒前
研友_VZG7GZ的应助被尚欣雨采纳,获得10
3秒前
bdsb完成签到,获得积分10
3秒前
pcm完成签到 ,获得积分10
3秒前
dd发布了新的文献求助10
3秒前
3秒前
3秒前
4秒前
拉拉啊了发布了新的文献求助10
4秒前
CX330发布了新的文献求助10
5秒前
Echogaogao完成签到,获得积分20
5秒前
tianyue完成签到,获得积分10
5秒前
chinjaneking完成签到,获得积分10
5秒前
5秒前
Ccc完成签到,获得积分10
5秒前
zclm发布了新的文献求助10
7秒前
威武爆米花完成签到,获得积分10
7秒前
Lila完成签到,获得积分10
7秒前
干净涵梅的应助被侯伟玮采纳,获得30
7秒前
虚幻中蓝发布了新的文献求助10
7秒前
8秒前
背后子骞完成签到,获得积分10
8秒前
8秒前
LeoXu完成签到,获得积分10
9秒前
浅池星完成签到 ,获得积分10
9秒前
空空完成签到,获得积分10
10秒前
阿萨姆拌粉完成签到,获得积分10
10秒前
dd完成签到,获得积分10
10秒前
12秒前
14秒前
777完成签到 ,获得积分10
15秒前
Lila发布了新的文献求助10
15秒前
小黑关注了科研通微信公众号
16秒前
绿豆酥发布了新的文献求助10
17秒前
wxz1236发布了新的文献求助10
17秒前
17秒前
吴宗翰完成签到,获得积分10
17秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191812
求助须知:如何正确求助?哪些是违规求助? 9578503
关于积分的说明 21859856
捐赠科研通 7791184
什么是DOI,文献DOI怎么找? 3436733
关于科研通互助平台的介绍 2560447
邀请新用户注册赠送积分活动 2483502